Latest news with #TheratechnologiesInc
Yahoo
29-05-2025
- Business
- Yahoo
Theratechnologies Reports on its Annual Meeting of Shareholders
MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ('Theratechnologies' or the 'Company') (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. Shareholders proceeded to elect the below candidates to the Company's Board of Directors for a one-year term, appointed KPMG LLP as the Company's auditors for the current fiscal year and approved the adoption of an omnibus long-term incentive plan for the benefits of the directors, executive officers and employees of the Company and those of its subsidiaries. All candidates proposed for the position of director were elected in the following proportion: FOR % FOR ABSTENTION % ABSTENTION Joseph Arena 20,473,944 84.03% 3,890,222 15.97% Frank Holler 19,089,786 78.35% 5,274,380 21.65% Paul Lévesque 19,027,772 78.10% 5,336,394 21.90% Andrew Molson 19,066,145 78.25% 5,298,021 21.75% Dawn Svoronos 18,998,230 77.98% 5,365,936 22.02% Elina Tea 19,163,502 78.65% 5,200,664 21.35% Dale Weil 19,005,768 78.01% 5,358,398 21.99% Jordan Zwick 19,618,725 80.52% 4,745,441 19.48% About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at on SEDAR+ at and on EDGAR at Follow Theratechnologies on Linkedin and X (formerly Twitter). Contacts: Investor inquiries:Philippe DubucSenior Vice President and Chief Financial Officerpdubuc@ Media inquiries:Julie SchneidermanSenior Director, Communications & Corporate Affairscommunications@ in to access your portfolio
Hamilton Spectator
02-05-2025
- Health
- Hamilton Spectator
Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV
VAMOS analysis highlights link between EVAF and reduced muscle quality Case series reports success with combination tesamorelin/GLP-1 receptor agonist therapy MONTREAL, May 02, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. ('Theratechnologies' or the 'Company') (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced two poster presentations at the 19th Annual American Conference for the Treatment of HIV (ACTHIV 2025), taking place May 1-3 in Chicago, Ill. Both presentations focus on issues surrounding excess visceral abdominal fat (EVAF), a common comorbidity in people with HIV (PWH). One poster presents a new analysis of data from the Visceral Adiposity Measurement and Observations Study (VAMOS), in which EVAF was associated with reduced muscle quality in aging PWH. VAMOS is the first trial designed to improve the understanding of the impact of EVAF on cardiovascular disease, steatotic liver disease, insulin resistance, and other metabolic parameters in PWH. The second presentation reports on a first-of-its-kind case series in which the combination of tesamorelin and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) therapy was highly effective in reducing both EVAF and obesity in a real-world setting. 'We are proud to continue our exploration into the complexities of excess visceral abdominal fat in people with HIV,' said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer of Theratechnologies. 'As people with HIV live longer, analyses such as the data we are presenting at ACTHIV are critical to addressing this population's evolving health needs. Our research adds to the growing understanding that body composition, most importantly EVAF, is a key factor in aging-related functional decline in HIV, and we are committed to investigating this complex relationship.' VAMOS Analysis Poster Title: Reduced Muscle Quality is Highly Prevalent in Aging People with HIV (PWH) and is Associated with Excess Visceral Abdominal Fat (EVAF) First Author: Zachary Henry, DO, AIDS Healthcare Foundation, Fort Lauderdale, Fla. In the latest analysis from the multicenter VAMOS study, researchers investigated how EVAF, compared to subcutaneous fat, is associated with muscle quality in PWH on modern anti-retroviral regimens, and explored potential drivers of this relationship. Among the 170 participants, EVAF prevalence was 58%. Muscle quality was found to be lower with increasing age of participants (r= -0.465; p<0.0001), but was not significantly correlated with body mass index (BMI) (r= -0.118; p=0.124). EVAF was associated with lower skeletal muscle quality, as demonstrated by lower muscle mean attenuation (r= -0.445; p<0.0001). The researchers concluded that increased levels of visceral fat – more so than subcutaneous fat or increasing BMI – strongly correlate with reduced skeletal muscle quality, which may amplify age-related functional declines. Tesamorelin/GLP-1 RA Case Series Poster Title: High Levels of Treatment Success Seen with Combined Use of Tesamorelin and GLP1-RAs in People with HIV First Author: Daniel Lee, MD, University of California San Diego Department of Medicine, San Diego, Calif. In the case series, investigators reported on the real-world use of tesamorelin for the treatment of EVAF in PWH, in combination with GLP-1 RAs, which are commonly used for diabetes and obesity management in the general population. Among the seven PWH evaluated in the case series, tesamorelin was initiated first in all cases to address EVAF, with a mean reduction in waist circumference of 1.3 inches. The principal reasons for adding a GLP-1-RA included improving BMI and diabetic control. Following at least six months of combination therapy, patients saw mean reductions in weight (-13 pounds), BMI (-2.2 kg/m2), and waist circumference (-3.4 inches), with six of the seven patients achieving their metabolic and body composition goals. Combination therapy is ongoing in most of the patients (6/7). This is the first known report of the dual use of these agents in PWH, highlighting their complementary but distinct mechanisms of action. 'The combination of tesamorelin and GLP-1 medications represents a new frontier in metabolic care for people with HIV,' noted Dr. Marsolais. 'By distinguishing between and targeting both excess visceral abdominal fat and generalized obesity, treatment strategies can be tailored to address the specific needs of people living with HIV.' Both posters can be found at and following the conference. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at , on SEDAR+ at and on EDGAR at . Follow Theratechnologies on LinkedIn and X . Forward-Looking Information This press release contains forward-looking statements and forward-looking information (collectively, the 'Forward-Looking Statements'), within the meaning of applicable securities laws, that are based on our management's beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as 'may', 'will', 'should', 'could', 'promising', 'would', 'outlook', 'believe', 'plan', 'envisage', 'anticipate', 'expect' and 'estimate', or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding the Company's commitment to investigate the relationship between body composition and aging and the tailoring of treatment strategies for PWH. Forward-looking statements involve a number of assumptions, risks and uncertainties. Some of these assumptions include, but are not limited to, the duration of treatment and the responses to the administered drugs by PWH. Some of the risks include that PWH may not respond similarly when they take medicines and results may differ from what those were observed and reported through VAMOS and the tesamorelin/GLP-1 RA case series. The Company refers current and potential investors to the 'Risk Factors' section of the Company's Annual Information Form filed on Form 20-F dated February 26, 2025 available on SEDAR+ at and on EDGAR at under Theratechnologies' public filings for the risks associated with the business of Theratechnologies. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent the Company's expectations as of that date. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law. Contacts: Media inquiries: Julie Schneiderman Senior Director, Communications & Corporate Affairs communications@ 514-336-7800 Investor Inquiries: Joanne Choi Senior Director, Investor Relations jchoi@ 551-261-0401
Yahoo
02-05-2025
- Health
- Yahoo
Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV
VAMOS analysis highlights link between EVAF and reduced muscle quality Case series reports success with combination tesamorelin/GLP-1 receptor agonist therapy MONTREAL, May 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ('Theratechnologies' or the 'Company') (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced two poster presentations at the 19th Annual American Conference for the Treatment of HIV (ACTHIV 2025), taking place May 1-3 in Chicago, Ill. Both presentations focus on issues surrounding excess visceral abdominal fat (EVAF), a common comorbidity in people with HIV (PWH). One poster presents a new analysis of data from the Visceral Adiposity Measurement and Observations Study (VAMOS), in which EVAF was associated with reduced muscle quality in aging PWH. VAMOS is the first trial designed to improve the understanding of the impact of EVAF on cardiovascular disease, steatotic liver disease, insulin resistance, and other metabolic parameters in PWH. The second presentation reports on a first-of-its-kind case series in which the combination of tesamorelin and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) therapy was highly effective in reducing both EVAF and obesity in a real-world setting. 'We are proud to continue our exploration into the complexities of excess visceral abdominal fat in people with HIV,' said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer of Theratechnologies. 'As people with HIV live longer, analyses such as the data we are presenting at ACTHIV are critical to addressing this population's evolving health needs. Our research adds to the growing understanding that body composition, most importantly EVAF, is a key factor in aging-related functional decline in HIV, and we are committed to investigating this complex relationship.' VAMOS Analysis Poster Title: Reduced Muscle Quality is Highly Prevalent in Aging People with HIV (PWH) and is Associated with Excess Visceral Abdominal Fat (EVAF) First Author: Zachary Henry, DO, AIDS Healthcare Foundation, Fort Lauderdale, Fla. In the latest analysis from the multicenter VAMOS study, researchers investigated how EVAF, compared to subcutaneous fat, is associated with muscle quality in PWH on modern anti-retroviral regimens, and explored potential drivers of this relationship. Among the 170 participants, EVAF prevalence was 58%. Muscle quality was found to be lower with increasing age of participants (r= -0.465; p<0.0001), but was not significantly correlated with body mass index (BMI) (r= -0.118; p=0.124). EVAF was associated with lower skeletal muscle quality, as demonstrated by lower muscle mean attenuation (r= -0.445; p<0.0001). The researchers concluded that increased levels of visceral fat – more so than subcutaneous fat or increasing BMI – strongly correlate with reduced skeletal muscle quality, which may amplify age-related functional declines. Tesamorelin/GLP-1 RA Case Series Poster Title: High Levels of Treatment Success Seen with Combined Use of Tesamorelin and GLP1-RAs in People with HIV First Author: Daniel Lee, MD, University of California San Diego Department of Medicine, San Diego, Calif. In the case series, investigators reported on the real-world use of tesamorelin for the treatment of EVAF in PWH, in combination with GLP-1 RAs, which are commonly used for diabetes and obesity management in the general population. Among the seven PWH evaluated in the case series, tesamorelin was initiated first in all cases to address EVAF, with a mean reduction in waist circumference of 1.3 inches. The principal reasons for adding a GLP-1-RA included improving BMI and diabetic control. Following at least six months of combination therapy, patients saw mean reductions in weight (-13 pounds), BMI (-2.2 kg/m2), and waist circumference (-3.4 inches), with six of the seven patients achieving their metabolic and body composition goals. Combination therapy is ongoing in most of the patients (6/7). This is the first known report of the dual use of these agents in PWH, highlighting their complementary but distinct mechanisms of action. 'The combination of tesamorelin and GLP-1 medications represents a new frontier in metabolic care for people with HIV,' noted Dr. Marsolais. 'By distinguishing between and targeting both excess visceral abdominal fat and generalized obesity, treatment strategies can be tailored to address the specific needs of people living with HIV.' Both posters can be found at and following the conference. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at on SEDAR+ at and on EDGAR at Follow Theratechnologies on LinkedIn and X. Forward-Looking Information This press release contains forward-looking statements and forward-looking information (collectively, the 'Forward-Looking Statements'), within the meaning of applicable securities laws, that are based on our management's beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as "may", "will", "should", "could", 'promising', 'would', "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding the Company's commitment to investigate the relationship between body composition and aging and the tailoring of treatment strategies for PWH. Forward-looking statements involve a number of assumptions, risks and uncertainties. Some of these assumptions include, but are not limited to, the duration of treatment and the responses to the administered drugs by PWH. Some of the risks include that PWH may not respond similarly when they take medicines and results may differ from what those were observed and reported through VAMOS and the tesamorelin/GLP-1 RA case series. The Company refers current and potential investors to the 'Risk Factors' section of the Company's Annual Information Form filed on Form 20-F dated February 26, 2025 available on SEDAR+ at and on EDGAR at under Theratechnologies' public filings for the risks associated with the business of Theratechnologies. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent the Company's expectations as of that date. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law. Contacts: Media inquiries:Julie SchneidermanSenior Director, Communications & Corporate Affairscommunications@ Investor Inquiries:Joanne ChoiSenior Director, Investor Relationsjchoi@ in to access your portfolio
Yahoo
20-04-2025
- Business
- Yahoo
Is Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?
We recently published a list of the . In this article, we are going to take a look at where Theratechnologies Inc. (NASDAQ:THTX) stands against other best rising penny stocks to buy according to analysts. The start of 2025 was characterized by a series of challenges for the US equities across the board. Tariffs, inflationary concerns, the risk of recession, and loss of consumer confidence, all led to the small-cap Russell 2000 Index falling 9.5% and the large-cap Russell 1000 Index falling 4.5%. On April 1, Royce Investment released its fiscal first quarter outlook for small-cap stocks. Francis Gannon, who is the Co-Chief Investment Officer, and Managing Director, noted that while the large-cap outperformed the small-caps, however, this performance was not concentrated among the Magnificent Seven, which has dominated the market previously. This is evident from the fact that the Russell Top 50 Index fell 7.6%, whereas the NASDAQ Composite was down more than 10.3%. Gannon highlighted that while the small-cap stocks underperformed the large caps, however, the divergence from the Mag Seven is a positive trend for the small-cap stocks. He noted that historically speaking the broadening of the market away from the top few stocks has meant good things for the small caps in the long term. Moreover, while dissecting the performance of small-cap equities during the downturn, Gannon noted that the Russell 2000 Value Index held better as compared to the Russell 2000 Growth Index. The small-cap value stocks have outperformed the growth counterparts over 1 and 5-year comparisons. However, when looked up from a 10-year standpoint the performance for both categories remains the same. Gannon further pointed out that during the first quarter of 2025, the biggest detractors of the Index were Information Technology, Industrials, Health Care, and Consumer Discretionary, while Utilities was the only positive contributor. Lasty, Gannon shared his experience of being a small-cap investment strategist for over 50 years. He highlighted it is still too early to tell if the first quarter drop for small-cap stocks was only short-term or indicates a long-term period of falling, however, he noted that corrections are common for the small-cap investors. Gannon advised investors to learn to be greedy when others are fearful and vice versa if they are interested in small caps. Moreover, looking at the stocks from a valuation standpoint, small caps remain largely undervalued as compared to large caps and Gannon advised the key to tackling periods of uncertainty is to remain invested. To compile the list of the 10 best-rising penny stocks to buy according to analysts, we used the Finviz stock screener and CNN. Using the screener, we aggregated the list of penny stocks (trading between $1 and $5) with more than 30% share price appreciation over the past month, and more than 30% average upside potential. Lastly, we sorted the list by market capitalization and ranked the stocks in ascending order of the number of hedge funds sourced from Insider Monkey's Q4 2024 database. Please note that the data was collected on April 17, 2025. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A futuristic healthcare facility, designed to address unmet medical needs. Theratechnologies Inc. (NASDAQ:THTX) is a pharmaceutical company based in Canada. It focuses on developing commercialized treatments for HIV, Oncology, and Nonalcoholic Steatohepatitis. The company currently markets two main prescription products for HIV in the United States including the EGRIFTA SV and Trogarzo. On April 11, Theratechnologies Inc. (NASDAQ:THTX) was upgraded to Buy from a Hold by The JonesResearch, with a price target of $3. Future Pak has made an offer to acquire the company, which the boards of directors are reviewing. Management has formed a special committee to evaluate the potential sale, however, analysts believe that it is unlikely that this offer would convert into a transaction. On the other hand, Theratechnologies Inc. (NASDAQ:THTX) has been doing well financially. It grew its revenue by 17% year-over-year to reach $19 million during the first quarter of 2025. The growth was driven by EGRIFTA SV sales which improved 44.8% during the same time. The stock has improved more than 65% over the past month, making it one of the best-rising penny stocks to buy according to analysts. Overall, THTX ranks 9th on our list of best rising penny stocks to buy according to analysts. While we acknowledge the potential of THTX to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than THTX but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
10-04-2025
- Business
- Yahoo
Theratechnologies Inc (THTX) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ...
Release Date: April 09, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Theratechnologies Inc (NASDAQ:THTX) reported a 17% growth in total revenues, reaching $19 million for the first quarter of 2025. The company's lead asset, GriftaSV, showed strong market momentum, contributing significantly to revenue growth. The new F8 formulation of Tessam Morland was approved, offering improved patient experience with once-weekly reconstitution. The company successfully resumed distribution of AgriftaSV after a temporary drug shortage, with patient numbers rebounding. Theratechnologies Inc (NASDAQ:THTX) achieved a positive adjusted EBITDA of $2.3 million, a significant improvement from the previous year's loss. The temporary drug shortage of AgriftaSV resulted in a sales loss of 6 to 7 weeks, impacting revenues by approximately $10 million. Q2 revenues are expected to be affected due to larger-than-usual orders at the end of Q1, leading to a longer drawdown period. Net sales of Trogarzo decreased by 22% year-over-year due to new competitors, with expectations of stabilization at lower levels. Selling expenses increased by 10% compared to the previous year, driven by higher stock-based compensation and professional fees. The company faces challenges in transitioning from AgriftaSV to AgriftaWR, with potential payer-related issues during the transition period. Warning! GuruFocus has detected 4 Warning Signs with THTX. Q: Are you looking for new products in the same therapeutic areas, and would you consider acquiring drugs that are already approved or in-licensing late-stage drug candidates? A: (Paul Leveck, CEO) We aim to make acquisitions that are accretive and focus on very late-stage drugs with a high chance of approval. Our priority is to find products that fit our current infrastructure to drive synergies, especially in the U.S. where we have a strong presence in community infectious disease. (John Leisure, Global Commercial Officer) We are exploring opportunities in synergistic areas and have identified potential targets, including assets already on the market. Q: How do you plan to facilitate the transition from Agrifta SV to Agrifta WR, and what is the expected timeline? A: (Paul Leveck, CEO) The transition needs to be well-orchestrated to avoid issues with payers. We plan a transition period similar to our previous experience from F1 to F4. (John Leisure, Global Commercial Officer) The process involves manufacturing and packaging the new product, updating pricing and NDC numbers, and managing the transition through our patient support program. We expect a transition period of about six months. Q: What are your medium to long-term expectations for growth in the Agrifta franchise? A: (Paul Leveck, CEO) The recognition of excess visceral abdominal fat as a cardiovascular risk factor is driving demand. We are seeing strong recovery post-drug shortage, indicating relevance. (John Leisure, Global Commercial Officer) Enrollments are up 15% year-to-date, and unique patients have bounced back, suggesting continued growth. Q: Why is there a continued negative impact on Trogarzo sales, and when do you expect stabilization? A: (John Leisure, Global Commercial Officer) The decline is due to losing more patients than gaining, despite stabilized enrollments. However, enrollments are up 16% year-to-date, indicating stabilization in utilization. Q: Do you foresee any tariff impacts on Trogarzo or the Iona products? A: (Paul Leveck, CEO) We do not anticipate issues with Trogarzo due to transfer pricing. (Philippe Debuk, CFO) The Iona products are manufactured in Europe and won't pass through the U.S. border, so we don't see any tariff risks. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
